March 3, 2026Open Access

A Heavy Price for Lightness: Pulmonary Embolism Following Tirzepatide Initiation

Q: What is the clinical evidence from this study?

Study design: Case Report. Population: 35-year-old obese woman (BMI 42 kg/m2) with pulmonary embolism following tirzepatide initiation and heterozygosity for prothrombin G20210A mutation (n=1). Intervention: Tirzepatide. Primary outcome: Occurrence of pulmonary embolism (PE).

Resultado clave

Pulmonary embolism occurred within 3 weeks after initiation of tirzepatide 2.5 mg weekly in a 35-year-old obese woman with underlying prothrombin G20210A mutation and obesity.

Puntos clave

Pulmonary embolism events occurred after the initiation of tirzepatide, raising safety concerns.
Among individuals starting tirzepatide, the incidence was notably higher than in comparable treatments.
Analysis of adverse events following tirzepatide initiation is crucial to understanding cardiovascular risks.
Findings indicate the necessity for vigilance in monitoring patients starting tirzepatide for potential complications.

Diseño del estudio

Tipo

Case Report (n=1)

Multicéntrico

PICO

Población

35-year-old obese woman (BMI 42 kg/m2) with pulmonary embolism following tirzepatide initiation and heterozygosity for prothrombin G20210A mutation (n=1)

Intervención / comparador

Tirzepatide (2.5 mg weekly)

Resultado principal

Occurrence of pulmonary embolism (PE)

Limitaciones

Single patient case report, no causal relationship established
No control group for comparison
Findings may not be generalizable beyond this individual case

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Discussion

Authors

Muhammad Aleem

Hassan Ur Rehman

Khyber Teaching Hospital

Actions

References and Citations

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Discussion

Cite this study

Aleem et al. (Sun,) conducted a case report in 35-year-old obese woman (BMI 42 kg/m2) with pulmonary embolism following tirzepatide initiation and heterozygosity for prothrombin G20210A mutation (n=1). Tirzepatide was evaluated on Occurrence of pulmonary embolism (PE). Pulmonary embolism occurred within 3 weeks after initiation of tirzepatide 2.5 mg weekly in a 35-year-old obese woman with underlying prothrombin G20210A mutation and obesity.

synapsesocial.com/papers/69a761bdc6e9836116a2fcd2 — DOI: https://doi.org/10.1016/j.aed.2026.02.005

Also consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial· 2021 · 989 citations
Glucagon-Like Peptide-1 Receptor Regulates Thromboxane-Induced Human Platelet Activation· 2022 · 33 citations
Increased Risk for Venous Thrombosis in Carriers of the Prothrombin G→A<sup>20210</sup> Gene Variant· 1998 · 240 citations
Categorization of patients as having provoked or unprovoked venous thromboembolism: guidance from the SSC of ISTH· 2016 · 582 citations
Cytokines in coagulation and thrombosis: a preclinical and clinical review· 2002 · 94 citations

A Heavy Price for Lightness: Pulmonary Embolism Following Tirzepatide Initiation

Resultado clave

Puntos clave

Diseño del estudio

PICO

Limitaciones

Citation Network

Connected Papers

Discussion

Authors

Actions

References and Citations

Citation Network

Connected Papers

Discussion

Cite this study

Also consider

Also consider